Sun Young Cho

Sun Young Cho

Auto-generated profile, based on publicly available information

Sun Young Cho

Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
HSHyeri Seok
Hyeri Seok
KHKyungmin Huh
Kyungmin Huh
SCSun Young Cho
Sun Young Cho
CKCheol-In Kang
Cheol-In Kang
DCDoo Ryeon Chung
Doo Ryeon Chung
KPKyong Ran Peck
Kyong Ran Peck
Background: Invasive fungal disease (IFD) is common in solid organ transplant (SOT) recipients and contributes to high morbidity and mortality. Although kidney transplantation (KT) is a commonly performed SOT, data on the risk factors for IFD-related mortality are limited. Methods: A 1:2 retrospective case-control study was performed in an experienced single center in the Republic of Korea. We reviewed the electronic medical records of patients with IFD after KT between February 1995 and March 2015. Results: Of 1963 kidney transplant recipients, 48 (2.5%) were diagnosed with IFD. The median interval from KT to IFD diagnosis was 172 days. Invasive aspergillosis (IA) was the most common, followed by invasive candidiasis (IC). Diabetes mellitus (DM) (odds ratio (OR) 3.72, 95% confidence interval (CI) 1.34–10.31, p = 0.011) and acute rejection (OR 3.41, 95% CI 1.41–8.21, p = 0.006) were associated with IFD development. In the subgroup analyses, concomitant bacterial infection was associated with IC development (OR 20.10, 95% CI 3.60–112.08, p = 0.001), and delayed graft function was associated with IA occurrence (OR 10.60, 95% CI 1.05–106.84, p = 0.045). The 12-week mortality rate in all patients was 50.0%. Mortality rates were significantly higher in older patients (adjusted hazard ratio (aHR) 1.06, 95% CI 1.02–1.11, p = 0.004), or those with DM (aHR 2.61, 95% CI 1.02–6.68, p = 0.044), deceased donor transplantation (aHR 2.68, 95% CI 1.03–6.95, p = 0.043), lymphocyte-depleting antibody usage (aHR 0.26, 95% CI 0.08–0.80, p = 0.019), acute rejection (aHR 0.38, 95% CI 0.15–0.97, p = 0.044), and concomitant bacterial infection (aHR 8.76, 95% CI 1.62–47.51, p = 0.012). Conclusions: A total of 50% of IFD cases occurred six months or later after transplantation. The IFD-related mortality rate was high in kidney transplant recipients despite the low incidence. DM and acute rejection were associated with high mortality, as well as IFD development. As old age, deceased donor transplantation, lymphocyte-depleting antibody usage, and concomitant bacterial infection are risk factors for IFD-related mortality, efforts for its early diagnosis and appropriate treatment are required.

1 January 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
IYIn Young Yoo
In Young Yoo
OKOn-Kyun Kang
On-Kyun Kang
MLMyoung-Keun Lee
Myoung-Keun Lee
YKYae-Jean Kim
Yae-Jean Kim
SCSun Young Cho
Sun Young Cho
NLNam Yong Lee
Nam Yong Lee
Yoo IY, et al. Ann Lab Med. 2020 Jan;40(1):63-67. https://doi.org/10.3343/alm.2020.40.1.63

3 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
JYJinyoung Yang
Jinyoung Yang
KLKyo Won Lee
Kyo Won Lee
JBJinYang Baek
JinYang Baek
SBSeongman Bae
Seongman Bae
YLYoung Ho Lee
Young Ho Lee
JKJae-Hoon Ko
Jae-Hoon Ko
Diminished immune response to coronavirus disease 2019 (COVID-19) vaccines and breakthrough infection (BI) is a major concern for solid organ transplant recipients. Humoral and cellular immune responses of kidney transplant (KT) recipients after a third COVID-19 vaccination were investigated compared to matched health care workers. Anti-severe acute respiratory syndrome coronavirus 2 spike protein antibody and severe acute respiratory syndrome coronavirus 2 specific interferon-gamma releasing assay (IGRA) were assessed. A total of 38 KT recipients, including 20 BI and 18 noninfection, were evaluated. In the KT BI group, antibody titers were significantly increased (median 5 to 724, binding antibody units/mL (P = 0.002) after the third vaccination, but IGRA responses were negligible. After BI, antibody titers increased (median 11 355 binding antibody unit/mL; P < 0.001) and there was a significant increase of IGRA responses to spike proteins (Spike1-Nil, median 0.05 to 0.41 IU/mL; P = 0.009). Antibody titers and IGRA responses were significantly higher in the BI than in the noninfection group after 6 months. Immune responses were stronger in the health care worker than in the KT cohort, but the gap became narrower after BI. In conclusion, KT recipients who experienced BI after 3 COVID-19 vaccinations acquired augmented humoral and cellular immune responses.

10 August 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ENEliel Nham
Eliel Nham
KHKyungmin Huh
Kyungmin Huh
YSYou Min Sohn
You Min Sohn
HPHyo Jung Park
Hyo Jung Park
HKHyemee Kim
Hyemee Kim
KPKyong Ran Peck
Kyong Ran Peck
Purpose: To find pharmacokinetic/pharmacodynamic parameters of vancomycin associated with the optimal outcome of severe infection due to Enterococcus species. Methods: We retrospectively reviewed enterococcal bacteremia cases treated with vancomycin from January 2015 to December 2020. The primary outcome was 30-day mortality. We calculated cutoff values of the ratio of vancomycin area under the concentration–time curve over 24 h to the minimum inhibitory concentration (AUC24/MIC) and trough concentration (Ctrough) during the initial 72 h of treatment. The optimal cutoff value was determined using the Youden index. Binary variables created based on these cutoffs were further assessed using multivariable analysis. Results: A total of 65 patients were included. The majority (87.7%) had solid or hematologic malignancies. Thirty-day mortality and nephrotoxicity occurred in nine (13.4%) and 14 (21.5%) patients, respectively. Both vancomycin AUC24/MIC and Ctrough showed fair performance in predicting 30-day mortality (AUC of receiver-operator curve for AUC24/MIC, 0.712; 95% confidence interval [CI] 0.539–0.886; AUC for Ctrough, 0.760; 95% CI 0.627–0.892; pairwise AUC comparison: p = 0.570). Ctrough ≥ 13.94 μg/mL, but not AUC24/MIC ≥ 504, had a significant association with 30-day mortality after adjusting for confounders (odds ratio, 8.40; 95% CI 1.60–86.62; p = 0.010). Conclusion: Mean Ctrough ≥ 13.94 μg/mL during the initial 72 h was associated with higher 30-day mortality in enterococcal bacteremia. Further studies are warranted to elucidate optimal pharmacokinetic targets for enterococcal bacteremia.

1 January 2017 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
GPGa Eun Park
Ga Eun Park
CKCheol-In Kang
Cheol-In Kang
JKJae-Hoon Ko
Jae-Hoon Ko
SCSun Young Cho
Sun Young Cho
YHYoung Eun Ha
Young Eun Ha
DCDoo Ryeon Chung
Doo Ryeon Chung
Park GE, et al. J Korean Med Sci. 2017 Jan;32(1):151-154. https://doi.org/10.3346/jkms.2017.32.1.151